A Population-Based Study of Genes Previously Implicated in Breast CancerChunling Hu, Celine M. Vachon, Kun Y. Lee et al.|New England Journal of Medicine|2021Cited by 862
A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.Kevin Kalinsky, Dawn L. Hershman, Melissa Accordino et al.|Journal of Clinical Oncology|2022Cited by 73